Bio-Rad Laboratories to Acquire Stilla Technologies to Expand Digital PCR Portfolio
Stilla Technologies to Be Acquired by Bio-Rad Laboratories to Increase Digital PCR Portfolio
A binding offer has been made by Bio-Rad Laboratories, Inc., a world leader in clinical diagnostics products and life science research, to purchase all ownership interests in Stilla Technologies (“Stilla”). The transaction is expected to close by the end of the third quarter of 2025, depending on regulatory approvals, employee representative consultation, and other standard closing requirements.
One of the top manufacturers of digital PCR equipment, consumables, and tests for the future is Stilla Technologies, which has operations in both France and the United States. Numerous genetic assays and molecular diagnostics are supported by its Nio® suite of all-in-one digital PCR instruments. These applications cover a wide range of domains, including as food and environmental testing, infectious disorders, organ transplant testing, cell and gene therapy, and liquid biopsy for oncology diagnostics.
Strategic Significance of the Purchase
“Stilla’s next-generation digital PCR solutions would make a compelling and complementary addition to Bio-Rad’s best-in-class digital PCR portfolio,” said Norman Schwartz, CEO of Bio-Rad Laboratories, highlighting the deal’s significance. After it closes, the acquisition will help us achieve our goal of growing our company into clinical diagnostics and applied research, where clients demand greater automation and throughput.
When combined with our upcoming launch of Bio-Rad’s QX ContinuumTM system, the Stilla platform would enable us to serve the entire spectrum of digital PCR applications and help us meet the evolving needs of customers in genomics research and applied science, said Jim Barry, Executive Vice President and President of Bio-Rad’s Life Science Group.
The Viewpoint of Stilla
Stilla Technologies CEO Rémi Dangla was excited about the acquisition, saying, “We are excited about the opportunity to join Bio-Rad, a leader in the field of digital PCR. Together, Stilla’s enthusiasm for product creation and Bio-Rad’s vast life science knowledge, operational excellence, and global presence allow us to significantly improve the work of biopharma and applied research clients worldwide.
Concerning Stilla Technologies
The Nio® digital PCR platforms from Stilla are all-in-one devices with sophisticated molecular assay and genetic testing features. They are a useful tool for researchers and physicians in a variety of specialised applications because of their cutting-edge technology, which makes accurate and effective workflows possible.
Through an enlarged product line that serves the applied research and clinical diagnostics markets, the acquisition will increase Bio-Rad’s market share in digital PCR technology. By making this acquisition, Bio-Rad hopes to improve automation and throughput capabilities, meeting the changing needs of clients in the applied sciences and genomics research.
Once completed, the deal will represent a major turning point in Bio-Rad’s plan to solidify its position as a leader in digital PCR technology and increase its presence in the applied science and clinical diagnostics sectors around the world.
